LGM Pharma launches analytical and stability testing as standalone service
The integrated CDMO rolls out services to the broader community of drug manufacturers and developers
LGM Pharma, a company offering integrated CDMO services, is launching its analytical services and facilities as a standalone contract service for drug developers and manufacturers.
The decision comes after the company's acquisition of Nexgen Pharma's formulation development and drug product contract manufacturing business last year, which LGM Pharma said "significantly expanded" its physical infrastructure and talent.
The additional 100,000 sq. ft of specialised facilities, equipment and 150 experienced staff with expertise in analytical and stability testing, along with expertise in all aspects of pharmaceutical finished product development and manufacturing, has placed LGM Pharma in a position to offer a full suite of these services as a standalone option.
The CDMO has a network of cGMP facilities in California, Colorado, and Texas, state-of-the-art chromatography and spectroscopy equipment, and more than 60 quality assurance, quality control and analytical staff members.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.